NCT03556852View on ClinicalTrials.gov

CARBETOCIN VERSUS RECTAL MISOPROSTOL FOR MANAGEMENT OF THIRD STAGE OF LABOR IN WOMEN AT LOW RISK OF POSTPARTUM HEMORRHAGE

PHASE4CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

July 2, 2018

Primary Completion Date

May 24, 2019

Study Completion Date

May 30, 2019

Conditions

Postpartum Hemorrhage

Interventions

DRUG

Carbetocin

1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby

DRUG

Misoprostol

2 rectal misoprostol tablets (800 μg) after the delivery of the baby.

Trial Locations (1)

12111

Kasr Alainy medical school, Cairo

All Listed Sponsors

lead

Cairo University

OTHER

NCT03556852 - CARBETOCIN VERSUS RECTAL MISOPROSTOL FOR MANAGEMENT OF THIRD STAGE OF LABOR IN WOMEN AT LOW RISK OF POSTPARTUM HEMORRHAGE | Biotech Hunter | Biotech Hunter